Osteoprotegerin (OPG) and Matrix Gla protein (MGP) in rheumatoid arthritis patients: Relation to disease activity

Egyptian Rheumatologist

Volumn 36, Issue 3, 2014, Pages 111-116

  Ghorbanihaghjo, Amir ^a   Hajialilo, Mehrzad ^b   Shahidi, Maryam ^b   khabazi, Alireza ^c   Kolahi, Susan ^c   Nakhjavani, Mohammad Reza Jafari ^a   Raeisi, Sina ^a   Argani, Hassan ^a   Rashtchizadeh, Nadereh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Disease activity score 28 CRP (DAS28 CRP); Matrix Gla protein (MGP); Osteoprotegerin (OPG); Rheumatoid arthritis (RA)

Indexed keywords

C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; MATRIX GLA PROTEIN; OSTEOPROTEGERIN; UNCLASSIFIED DRUG; AZATHIOPRINE; CYCLOSPORIN; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; PREDNISONE; PROTEIN MGP; SALAZOSULFAPYRIDINE;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; AGE DISTRIBUTION; AGED; CORRELATION COEFFICIENT; LABORATORY TEST; SENSITIVITY ANALYSIS; SEX DIFFERENCE;

EID: 84901391113     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2014.01.003     Document Type: Article

References (53)

1. Bolon B., Shalhoub V., Kostenuik P.J., Campagnuolo G., Morony S., Boyle W.J., et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum 2002, 46(12):3121-3135.
2. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390(6656):175-179.
3. Tat S.K., Pelletier J.P., Velasco C.R., Padrines M., Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?. Keio J Med 2009, 58(1):29-40.
4. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141(9):3478-3484.
5. Itonaga I., Fujikawa Y., Sabokbar A., Murray D.W., Athanasou N.A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000, 192(1):97-104.
6. Wagner E.F., Karsenty G. Genetic control of skeletal development. Curr Opin Genet Dev 2001, 11(5):527-532.
7. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2):309-319.
8. Trouvin A.P., Goeb V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010, 5:345-354.
9. Frick K.K., Bushinsky D.A. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. J Bone Miner Res 2003, 18(7):1317-1325.
10. Alkady E.A., Rashad S.M., Khedr T.M., Mosad E., Abdel-Wahab N. Early predictors of increased bone resorption in juvenile idiopathic arthritis: OPG/RANKL ratio, as a key regulator of bone metabolism. Egyptian Rheumatol 2011, 33(4):217-223.
11. Skoumal M., Kolarz G., Haberhauer G., Woloszczuk W., Hawa G., Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005, 26(1):63-69.
12. Vega D., Maalouf N.M., Sakhaee K. CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92(12):4514-4521.
13. Gheita T., Fawzy S., Rizk A., Hussein H. Impaired bone formation and osteoporosis in postmenopausal elderly onset rheumatoid arthritis patients. Egyptian Rheumatol 2011, 33(3):155-162.
14. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402(6759):304-309.
15. Lo Iacono N., Pangrazio A., Abinun M., Bredius R., Zecca M., Blair H.C., et al. RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease. Clin Dev Immunol 2013, 2013:412768.
16. Liu S., Shi W., Xiao H., Liang X., Deng C., Ye Z., et al. Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. PLoS One 2012, 7(7):e41331.
17. Saidenberg-Kermanac'h N., Cohen-Solal M., Bessis N., De Vernejoul M.C., Boissier M.C. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 2004, 71(1):9-13.
18. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159(5):1689-1699.
19. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46(7):1744-1753.
20. Wright H.L., McCarthy H.S., Middleton J., Marshall M.J. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009, 2(1):56-64.
21. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44(5):1003-1012.
22. Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012, 4(4):225-233.
23. Bezerra M.C., Carvalho J.F., Prokopowitsch A.S., Pereira R.M. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 2005, 38(2):161-170.
24. Farzaneh-Far A., Proudfoot D., Shanahan C., Weissberg P.L. Vascular and valvar calcification: recent advances. Heart 2001, 85(1):13-17.
25. Julien M., Khoshniat S., Lacreusette A., Gatius M., Bozec A., Wagner E.F., et al. Phosphate-dependent regulation of MGP in osteoblasts: role of ERK1/2 and Fra-1. J Bone Miner Res 2009, 24(11):1856-1868.
26. Parker B.D., Ix J.H., Cranenburg E.C., Vermeer C., Whooley M.A., Schurgers L.J. Association of kidney function and uncarboxylated Matrix Gla protein: data from the heart and soul study. Nephrol Dial Transplant 2009, 24(7):2095-2101.
27. Proudfoot D., Shanahan C.M. Molecular mechanisms mediating vascular calcification: role of Matrix Gla protein. Nephrology (Carlton) 2006, 11(5):455-461.
28. Jono S., Shioi A., Ikari Y., Nishizawa Y. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006, 24(2):176-181.
29. O'Young J., Liao Y., Xiao Y., Jalkanen J., Lajoie G., Karttunen M., et al. Matrix Gla protein inhibits ectopic calcification by a direct interaction with hydroxyapatite crystals. J Am Chem Soc 2011, 133(45):18406-18412.
30. Herrmann S.M., Whatling C., Brand E., Nicaud V., Gariepy J., Simon A., et al. Polymorphisms of the human Matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000, 20(11):2386-2393.
31. Moe S.M., Reslerova M., Ketteler M., O'Neill K., Duan D., Koczman J., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005, 67(6):2295-2304.
32. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumat 2010, 62(9):2569-2581.
33. Matsui T., Kuga Y., Kaneko A., Nishino J., Eto Y., Chiba N., et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheumatic Dis 2007, 66(9):1221-1226.
34. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30(2):340-346.
35. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010, 30(9):1849-1854.
36. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99(4):513-518.
37. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106(10):1192-1194.
38. Asanuma Y., Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007, 195(2):e135-e141.
39. Mogelvang R., Pedersen S.H., Flyvbjerg A., Bjerre M., Iversen A.Z., Galatius S., et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012, 109(4):515-520.
40. Alsalawy A.M., Fathi A.I., Kamel R.A., Ewis I. Correlation between serum osteoprotegerin and atherosclerotic vascular disorders in rheumatoid arthritis patients. Egyptian Rheumatol 2012, 34(1):35-42.
41. Asanuma Y.F., Shimada Y., Kouzu N., Yokota K., Nakajima K., Sato K., et al. Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 2013, 1-7.
42. Rhee E.J., Lee W.Y., Kim S.Y., Kim B.J., Sung K.C., Kim B.S., et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (London) 2005, 108(3):237-243.
43. Dingli D., Russell S.J. Mouse models and the RANKL/OPG axis in myeloma bone disease. Leukemia 2007, 21(10):2090-2093.
44. Chung C.P., Oeser A., Raggi P., Gebretsadik T., Shintani A.K., Sokka T., et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005, 52(10):3045-3053.
45. Yiu K.H., Wang S., Mok M.Y., Ooi G.C., Khong P.L., Lau C.S., et al. Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2011, 38(4):621-627.
46. Profumo E., Di Franco M., Buttari B., Masella R., Filesi C., Tosti M.E., et al. Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders. Mediators Inflamm 2012, 2012:503942.
47. Dellegrottaglie S., Sanz J., Rajagopalan S. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med 2006, 6(5):515-524.
48. Sinha S., Eddington H., Kalra P.A. Vascular calcification: lessons from scientific models. J Ren Care 2009, 35(Suppl 1):51-56.
49. Lomashvili K.A., Wang X., Wallin R., O'Neill W.C. Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. J Biol Chem 2011, 286(33):28715-28722.
50. Schurgers L.J., Barreto D.V., Barreto F.C., Liabeuf S., Renard C., Magdeleyns E.J., et al. The circulating inactive form of Matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010, 5(4):568-575.
51. Cranenburg E.C., Brandenburg V.M., Vermeer C., Stenger M., Muhlenbruch G., Mahnken A.H., et al. Uncarboxylated Matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009, 101(2):359-366.
52. Misra D., Booth S.L., Crosier M.D., Ordovas J.M., Felson D.T., Neogi T. Matrix Gla protein polymorphism, but not concentrations, is associated with radiographic hand osteoarthritis. J Rheumatol 2011, 38(9):1960-1965.
53. Frassetto L.A., Morris R.C., Sebastian A. Effect of age on blood acid-base composition in adult humans: role of age-related renal functional decline. Am J Physiol 1996, 271(6 Pt 2):F1114-F1122.